Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 52 | 2023 | 5445 | 1.780 |
Why?
|
Transplantation Conditioning | 37 | 2023 | 1599 | 1.540 |
Why?
|
Leukemia, Myeloid, Acute | 16 | 2023 | 3524 | 0.790 |
Why?
|
Graft vs Host Disease | 24 | 2022 | 2958 | 0.750 |
Why?
|
Bone Marrow Transplantation | 19 | 2020 | 2765 | 0.690 |
Why?
|
Cord Blood Stem Cell Transplantation | 8 | 2019 | 314 | 0.690 |
Why?
|
Hematologic Neoplasms | 19 | 2019 | 1832 | 0.670 |
Why?
|
Busulfan | 8 | 2015 | 263 | 0.500 |
Why?
|
Transplantation, Homologous | 22 | 2019 | 4777 | 0.480 |
Why?
|
Lymphoma, Non-Hodgkin | 7 | 2014 | 1381 | 0.430 |
Why?
|
Myeloablative Agonists | 4 | 2014 | 218 | 0.390 |
Why?
|
Transplantation Chimera | 12 | 2019 | 613 | 0.390 |
Why?
|
Hematologic Diseases | 3 | 2023 | 498 | 0.390 |
Why?
|
Lymphoma | 7 | 2022 | 1877 | 0.380 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2016 | 491 | 0.380 |
Why?
|
Cyclophosphamide | 15 | 2023 | 2242 | 0.370 |
Why?
|
Transplantation, Autologous | 19 | 2017 | 2124 | 0.360 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 18 | 2022 | 11525 | 0.360 |
Why?
|
Stem Cell Transplantation | 7 | 2015 | 1620 | 0.350 |
Why?
|
Niacinamide | 3 | 2016 | 416 | 0.330 |
Why?
|
Phenylurea Compounds | 3 | 2016 | 528 | 0.310 |
Why?
|
Immunoconjugates | 3 | 2019 | 901 | 0.290 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 1520 | 0.290 |
Why?
|
Histocompatibility Testing | 8 | 2019 | 741 | 0.270 |
Why?
|
Myeloproliferative Disorders | 2 | 2022 | 606 | 0.260 |
Why?
|
Vidarabine | 5 | 2019 | 345 | 0.250 |
Why?
|
Kidney Failure, Chronic | 6 | 2019 | 2535 | 0.250 |
Why?
|
Central Nervous System Neoplasms | 3 | 2022 | 895 | 0.240 |
Why?
|
Whole-Body Irradiation | 2 | 2019 | 449 | 0.240 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1271 | 0.210 |
Why?
|
Kidney Transplantation | 6 | 2019 | 4251 | 0.210 |
Why?
|
Antigens, CD19 | 2 | 2022 | 380 | 0.200 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 215 | 0.190 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.180 |
Why?
|
Blast Crisis | 1 | 2020 | 103 | 0.180 |
Why?
|
Heart Murmurs | 1 | 2020 | 94 | 0.180 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2013 | 272 | 0.180 |
Why?
|
Myelodysplastic Syndromes | 3 | 2015 | 1352 | 0.180 |
Why?
|
Hodgkin Disease | 2 | 2011 | 1415 | 0.170 |
Why?
|
Disease-Free Survival | 15 | 2019 | 6896 | 0.170 |
Why?
|
Sarcoma, Myeloid | 1 | 2020 | 59 | 0.170 |
Why?
|
Granulocyte Colony-Stimulating Factor | 5 | 2007 | 648 | 0.170 |
Why?
|
Middle Aged | 68 | 2022 | 213390 | 0.170 |
Why?
|
Long QT Syndrome | 1 | 2023 | 453 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 4 | 2007 | 227 | 0.160 |
Why?
|
Antifungal Agents | 2 | 2020 | 729 | 0.160 |
Why?
|
Fetal Blood | 3 | 2016 | 1318 | 0.160 |
Why?
|
Tandem Repeat Sequences | 2 | 2016 | 185 | 0.160 |
Why?
|
Aged | 50 | 2022 | 163288 | 0.160 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 290 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 334 | 0.150 |
Why?
|
Cytarabine | 5 | 2019 | 692 | 0.140 |
Why?
|
HLA Antigens | 4 | 2019 | 1382 | 0.140 |
Why?
|
Lymphocyte Transfusion | 3 | 2008 | 236 | 0.140 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 340 | 0.140 |
Why?
|
Adult | 57 | 2022 | 214052 | 0.140 |
Why?
|
Heart Neoplasms | 1 | 2020 | 374 | 0.140 |
Why?
|
Melphalan | 3 | 2019 | 431 | 0.140 |
Why?
|
Histocompatibility | 3 | 2009 | 330 | 0.140 |
Why?
|
Bacteremia | 2 | 2020 | 963 | 0.140 |
Why?
|
Graft vs Tumor Effect | 2 | 2008 | 72 | 0.140 |
Why?
|
Remission Induction | 7 | 2022 | 2385 | 0.140 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2022 | 1581 | 0.130 |
Why?
|
Eosinophilia | 1 | 2020 | 541 | 0.130 |
Why?
|
Humans | 99 | 2023 | 744366 | 0.130 |
Why?
|
Arabinonucleosides | 1 | 2015 | 35 | 0.130 |
Why?
|
Adenine Nucleotides | 1 | 2015 | 121 | 0.130 |
Why?
|
Etoposide | 2 | 2019 | 641 | 0.130 |
Why?
|
Multiple Myeloma | 6 | 2019 | 5181 | 0.130 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 689 | 0.130 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 246 | 0.130 |
Why?
|
Male | 62 | 2022 | 350115 | 0.130 |
Why?
|
Female | 67 | 2022 | 380193 | 0.120 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2018 | 360 | 0.120 |
Why?
|
Combined Modality Therapy | 13 | 2018 | 8642 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2022 | 2540 | 0.120 |
Why?
|
Urate Oxidase | 1 | 2014 | 35 | 0.120 |
Why?
|
Bone Marrow | 3 | 2020 | 2948 | 0.120 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 693 | 0.120 |
Why?
|
Graft Survival | 8 | 2019 | 3737 | 0.110 |
Why?
|
Quality of Life | 5 | 2018 | 12802 | 0.110 |
Why?
|
Parathyroid Hormone | 2 | 2012 | 1800 | 0.110 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2014 | 437 | 0.110 |
Why?
|
Maximum Tolerated Dose | 4 | 2019 | 892 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1199 | 0.110 |
Why?
|
Immune Tolerance | 5 | 2019 | 2259 | 0.110 |
Why?
|
Integrin alpha4 | 1 | 2012 | 92 | 0.110 |
Why?
|
Antineoplastic Agents | 7 | 2016 | 13693 | 0.110 |
Why?
|
Integrin beta Chains | 1 | 2012 | 121 | 0.110 |
Why?
|
Carmustine | 1 | 2012 | 137 | 0.100 |
Why?
|
Palliative Care | 2 | 2017 | 3493 | 0.100 |
Why?
|
Respirovirus Infections | 1 | 2011 | 50 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 655 | 0.100 |
Why?
|
Sirolimus | 2 | 2016 | 1565 | 0.100 |
Why?
|
Recurrence | 5 | 2023 | 8340 | 0.100 |
Why?
|
Leukocytosis | 1 | 2012 | 247 | 0.100 |
Why?
|
Pyrimidines | 2 | 2021 | 2943 | 0.100 |
Why?
|
Survival Analysis | 11 | 2018 | 10252 | 0.090 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 407 | 0.090 |
Why?
|
Affect | 2 | 2015 | 1475 | 0.090 |
Why?
|
Health Resources | 1 | 2016 | 911 | 0.090 |
Why?
|
Treatment Outcome | 22 | 2022 | 63107 | 0.090 |
Why?
|
Mycoses | 1 | 2013 | 376 | 0.090 |
Why?
|
Chromosome Deletion | 1 | 2014 | 1401 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2017 | 4479 | 0.090 |
Why?
|
Survival Rate | 9 | 2015 | 12788 | 0.080 |
Why?
|
Young Adult | 17 | 2020 | 56429 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5534 | 0.080 |
Why?
|
Retrospective Studies | 23 | 2021 | 77460 | 0.080 |
Why?
|
Virus Activation | 1 | 2010 | 319 | 0.080 |
Why?
|
Thymus Gland | 3 | 2010 | 1267 | 0.080 |
Why?
|
Intestinal Diseases | 1 | 2012 | 530 | 0.080 |
Why?
|
Drug Administration Schedule | 5 | 2019 | 4933 | 0.070 |
Why?
|
Carcinoma | 1 | 1999 | 2375 | 0.070 |
Why?
|
Hepatitis B virus | 1 | 2010 | 513 | 0.070 |
Why?
|
Viremia | 1 | 2010 | 736 | 0.070 |
Why?
|
Caregivers | 2 | 2016 | 2095 | 0.070 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2023 | 871 | 0.070 |
Why?
|
Pilot Projects | 4 | 2019 | 8319 | 0.070 |
Why?
|
Hepatitis B, Chronic | 1 | 2010 | 393 | 0.070 |
Why?
|
Ovarian Neoplasms | 2 | 2001 | 4839 | 0.070 |
Why?
|
Immunologic Memory | 1 | 2012 | 1348 | 0.070 |
Why?
|
Carboplatin | 4 | 2002 | 801 | 0.070 |
Why?
|
Idarubicin | 2 | 2019 | 62 | 0.070 |
Why?
|
Cytomegalovirus | 1 | 2010 | 733 | 0.060 |
Why?
|
Antibodies, Monoclonal | 4 | 2010 | 9274 | 0.060 |
Why?
|
Vincristine | 2 | 2022 | 1039 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2013 | 9240 | 0.060 |
Why?
|
Interleukin-2 | 2 | 2003 | 1904 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 2 | 2011 | 3773 | 0.060 |
Why?
|
Amyloidosis | 1 | 2010 | 796 | 0.060 |
Why?
|
Thiotepa | 2 | 2014 | 66 | 0.060 |
Why?
|
Immunosuppressive Agents | 5 | 2019 | 4153 | 0.060 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2009 | 220 | 0.060 |
Why?
|
Cytomegalovirus Infections | 1 | 2010 | 820 | 0.060 |
Why?
|
Hematopoietic Stem Cells | 1 | 1996 | 3390 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2018 | 4245 | 0.050 |
Why?
|
Acute Disease | 4 | 2017 | 7147 | 0.050 |
Why?
|
Lymphopoiesis | 1 | 2002 | 135 | 0.050 |
Why?
|
Tacrolimus | 2 | 2016 | 743 | 0.050 |
Why?
|
Salvage Therapy | 3 | 2009 | 1275 | 0.050 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2022 | 165 | 0.050 |
Why?
|
Massachusetts | 3 | 2021 | 8662 | 0.050 |
Why?
|
Boron Compounds | 1 | 2022 | 178 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.050 |
Why?
|
Graft Rejection | 5 | 2006 | 4397 | 0.050 |
Why?
|
Incidence | 4 | 2023 | 20952 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2018 | 5077 | 0.050 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39052 | 0.050 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1378 | 0.050 |
Why?
|
Pneumonia | 1 | 2012 | 2133 | 0.040 |
Why?
|
Pneumocystis | 1 | 1999 | 57 | 0.040 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2017 | 4266 | 0.040 |
Why?
|
Depression | 3 | 2016 | 7759 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2019 | 152 | 0.040 |
Why?
|
Lymphocytes | 2 | 2010 | 2617 | 0.040 |
Why?
|
Naphthoquinones | 1 | 1999 | 77 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2022 | 2649 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2017 | 2988 | 0.040 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2001 | 255 | 0.040 |
Why?
|
Adolescent | 15 | 2017 | 85779 | 0.040 |
Why?
|
Tissue Donors | 3 | 2010 | 2241 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2011 | 2987 | 0.040 |
Why?
|
Methotrexate | 2 | 2016 | 1728 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4034 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5321 | 0.040 |
Why?
|
Glycine | 1 | 2022 | 671 | 0.040 |
Why?
|
Arthritis, Gouty | 1 | 1998 | 28 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 315 | 0.040 |
Why?
|
Neoplasms | 4 | 2020 | 21696 | 0.040 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1999 | 249 | 0.040 |
Why?
|
Leukocyte Transfusion | 3 | 2003 | 60 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 369 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2010 | 3112 | 0.040 |
Why?
|
Parent-Child Relations | 1 | 2002 | 747 | 0.040 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1782 | 0.040 |
Why?
|
Living Donors | 2 | 1999 | 621 | 0.040 |
Why?
|
Spleen | 1 | 2023 | 2362 | 0.040 |
Why?
|
Boronic Acids | 2 | 2013 | 965 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 955 | 0.030 |
Why?
|
Leukapheresis | 1 | 1996 | 131 | 0.030 |
Why?
|
Lung | 1 | 2014 | 9857 | 0.030 |
Why?
|
Body Mass Index | 1 | 2013 | 12721 | 0.030 |
Why?
|
Inpatients | 2 | 2017 | 2518 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 639 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 1999 | 841 | 0.030 |
Why?
|
Pyrazines | 2 | 2013 | 1230 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5692 | 0.030 |
Why?
|
Hospitals, University | 1 | 2016 | 570 | 0.030 |
Why?
|
Bangladesh | 1 | 2016 | 687 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2003 | 2133 | 0.030 |
Why?
|
Dermatitis, Exfoliative | 1 | 2014 | 28 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 12073 | 0.030 |
Why?
|
Risk Factors | 6 | 2019 | 72296 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 402 | 0.030 |
Why?
|
Hospitalization | 4 | 2017 | 10259 | 0.030 |
Why?
|
Cytogenetic Analysis | 1 | 2014 | 295 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6621 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1584 | 0.030 |
Why?
|
Age Factors | 3 | 2015 | 18373 | 0.030 |
Why?
|
Family | 2 | 2007 | 3147 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 903 | 0.030 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2011 | 24 | 0.030 |
Why?
|
Antilymphocyte Serum | 2 | 2007 | 492 | 0.030 |
Why?
|
Cryopreservation | 1 | 2016 | 670 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2018 | 814 | 0.030 |
Why?
|
Mutation | 2 | 2014 | 29786 | 0.020 |
Why?
|
Flow Cytometry | 3 | 2012 | 5974 | 0.020 |
Why?
|
Pulmonary Edema | 1 | 2014 | 414 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2012 | 258 | 0.020 |
Why?
|
Cough | 1 | 2014 | 555 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 1972 | 0.020 |
Why?
|
Aftercare | 1 | 2017 | 870 | 0.020 |
Why?
|
Cell Separation | 1 | 2016 | 1751 | 0.020 |
Why?
|
Neutrophils | 2 | 2016 | 3721 | 0.020 |
Why?
|
Hepatitis Antibodies | 1 | 2010 | 73 | 0.020 |
Why?
|
Mediastinum | 1 | 2012 | 267 | 0.020 |
Why?
|
Interferon-gamma | 2 | 2010 | 3207 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2274 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2460 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 640 | 0.020 |
Why?
|
Fatigue | 1 | 2016 | 1531 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2010 | 418 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 651 | 0.020 |
Why?
|
Nasopharynx | 1 | 2011 | 379 | 0.020 |
Why?
|
Attitude to Health | 1 | 1998 | 2052 | 0.020 |
Why?
|
Administration, Inhalation | 1 | 2011 | 1105 | 0.020 |
Why?
|
Prognosis | 3 | 2015 | 29060 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2012 | 4386 | 0.020 |
Why?
|
Serologic Tests | 1 | 2010 | 374 | 0.020 |
Why?
|
T-Lymphocytes | 4 | 2014 | 10183 | 0.020 |
Why?
|
Alanine | 1 | 2010 | 572 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2018 | 2055 | 0.020 |
Why?
|
Uric Acid | 1 | 2014 | 766 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5172 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 890 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 72 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2278 | 0.020 |
Why?
|
Syndrome | 1 | 2014 | 3252 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 145 | 0.020 |
Why?
|
Time Factors | 6 | 2008 | 40075 | 0.020 |
Why?
|
Cardiotonic Agents | 1 | 2010 | 535 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 150 | 0.020 |
Why?
|
Filgrastim | 1 | 2007 | 133 | 0.020 |
Why?
|
Chest Pain | 1 | 2014 | 1114 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2455 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2011 | 1617 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 6036 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2017 | 1622 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2020 | 57776 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2009 | 546 | 0.020 |
Why?
|
Heart Failure | 1 | 2010 | 10895 | 0.020 |
Why?
|
Dyspnea | 1 | 2014 | 1303 | 0.020 |
Why?
|
Fever | 1 | 2014 | 1616 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4446 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2011 | 847 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2007 | 343 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2018 | 3395 | 0.020 |
Why?
|
Patient Care Team | 1 | 2016 | 2531 | 0.020 |
Why?
|
Prednisone | 1 | 2010 | 1574 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2012 | 10943 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 1880 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 810 | 0.020 |
Why?
|
Haplotypes | 2 | 2003 | 2779 | 0.020 |
Why?
|
Family Health | 2 | 2002 | 1281 | 0.020 |
Why?
|
Cell Count | 1 | 2009 | 1856 | 0.020 |
Why?
|
Developing Countries | 1 | 2016 | 2815 | 0.010 |
Why?
|
Antigens, Differentiation | 1 | 2007 | 927 | 0.010 |
Why?
|
Host vs Graft Reaction | 1 | 2003 | 14 | 0.010 |
Why?
|
Treatment Failure | 1 | 2010 | 2618 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7184 | 0.010 |
Why?
|
Skin Diseases | 1 | 2012 | 1066 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2008 | 2327 | 0.010 |
Why?
|
Cohort Studies | 4 | 2010 | 40559 | 0.010 |
Why?
|
Protozoan Infections | 1 | 2003 | 39 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2234 | 0.010 |
Why?
|
Receptors, KIR | 1 | 2003 | 113 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4894 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 7023 | 0.010 |
Why?
|
Haploidy | 1 | 2003 | 136 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1062 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5524 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2019 | 15297 | 0.010 |
Why?
|
Viral Load | 1 | 2011 | 3300 | 0.010 |
Why?
|
Hematopoiesis | 2 | 2005 | 2073 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4293 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1999 | 9955 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7182 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 2002 | 315 | 0.010 |
Why?
|
Aspergillosis | 1 | 2003 | 235 | 0.010 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2003 | 232 | 0.010 |
Why?
|
Lymphocyte Depletion | 1 | 2003 | 608 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 2001 | 257 | 0.010 |
Why?
|
Negotiating | 1 | 2002 | 133 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 2031 | 0.010 |
Why?
|
Chronic Disease | 1 | 2015 | 9145 | 0.010 |
Why?
|
Graft Enhancement, Immunologic | 1 | 2000 | 59 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2001 | 323 | 0.010 |
Why?
|
Breast Neoplasms | 2 | 2000 | 20824 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2007 | 1613 | 0.010 |
Why?
|
Atovaquone | 1 | 1999 | 58 | 0.010 |
Why?
|
Oxygen | 1 | 2011 | 4189 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2003 | 1369 | 0.010 |
Why?
|
Graft vs Leukemia Effect | 1 | 2000 | 111 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2007 | 2007 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3921 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2009 | 6539 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2014 | 13991 | 0.010 |
Why?
|
Leukemia, Myeloid | 1 | 2002 | 707 | 0.010 |
Why?
|
Blood Platelets | 1 | 2009 | 2509 | 0.010 |
Why?
|
Chimera | 1 | 1999 | 485 | 0.010 |
Why?
|
Neutropenia | 1 | 2003 | 895 | 0.010 |
Why?
|
Stroke Volume | 1 | 2010 | 5006 | 0.010 |
Why?
|
Prospective Studies | 3 | 2014 | 53290 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2003 | 1423 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2003 | 1366 | 0.010 |
Why?
|
Virus Diseases | 1 | 2003 | 711 | 0.010 |
Why?
|
Cyclosporine | 1 | 2000 | 788 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4026 | 0.010 |
Why?
|
Kinetics | 1 | 2002 | 6476 | 0.010 |
Why?
|
Hospice Care | 1 | 2002 | 672 | 0.010 |
Why?
|
Mass Screening | 1 | 2010 | 5253 | 0.010 |
Why?
|
Animals | 4 | 2010 | 168768 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5749 | 0.010 |
Why?
|
Mice | 3 | 2008 | 81201 | 0.010 |
Why?
|
Paclitaxel | 1 | 2001 | 1708 | 0.010 |
Why?
|
Models, Psychological | 1 | 1998 | 811 | 0.010 |
Why?
|
United States | 1 | 2021 | 69872 | 0.010 |
Why?
|
Personal Satisfaction | 1 | 1998 | 643 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2013 | 6486 | 0.010 |
Why?
|
Safety | 1 | 1998 | 1186 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7282 | 0.010 |
Why?
|
Models, Animal | 1 | 2000 | 2173 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1998 | 2971 | 0.010 |
Why?
|
Self Concept | 1 | 1998 | 1025 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2008 | 9445 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 15078 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2009 | 5035 | 0.010 |
Why?
|
ROC Curve | 1 | 1998 | 3528 | 0.010 |
Why?
|
Stem Cells | 1 | 2003 | 3567 | 0.010 |
Why?
|
Cell Survival | 1 | 2000 | 5882 | 0.010 |
Why?
|
Bacterial Infections | 1 | 1998 | 1401 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2008 | 18034 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2000 | 4851 | 0.010 |
Why?
|
Boston | 1 | 2002 | 9312 | 0.010 |
Why?
|
Regression Analysis | 1 | 1998 | 6459 | 0.000 |
Why?
|
Decision Making | 1 | 2002 | 3888 | 0.000 |
Why?
|
Child, Preschool | 2 | 2002 | 41005 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 7914 | 0.000 |
Why?
|
Heart Diseases | 1 | 2000 | 2789 | 0.000 |
Why?
|
Odds Ratio | 1 | 1998 | 9849 | 0.000 |
Why?
|
Genotype | 1 | 2000 | 12952 | 0.000 |
Why?
|
Multivariate Analysis | 1 | 1998 | 12244 | 0.000 |
Why?
|
Pain | 1 | 1998 | 4988 | 0.000 |
Why?
|
Registries | 1 | 1998 | 8091 | 0.000 |
Why?
|
Phenotype | 1 | 2000 | 16367 | 0.000 |
Why?
|
Child | 2 | 2002 | 77709 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2000 | 19905 | 0.000 |
Why?
|
Neoplasm Staging | 1 | 1995 | 11031 | 0.000 |
Why?
|
Pregnancy | 1 | 2001 | 29144 | 0.000 |
Why?
|